EDIT
Price
$2.76
Change
+$0.03 (+1.10%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
228.54M
12 days until earnings call
TGTX
Price
$37.89
Change
-$1.30 (-3.32%)
Updated
Jul 18, 04:59 PM (EDT)
Capitalization
6.22B
18 days until earnings call
Interact to see
Advertisement

EDIT vs TGTX

Header iconEDIT vs TGTX Comparison
Open Charts EDIT vs TGTXBanner chart's image
Editas Medicine
Price$2.76
Change+$0.03 (+1.10%)
Volume$35.38K
Capitalization228.54M
TG Therapeutics
Price$37.89
Change-$1.30 (-3.32%)
Volume$15.2K
Capitalization6.22B
EDIT vs TGTX Comparison Chart in %
Loading...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EDIT vs. TGTX commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and TGTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (EDIT: $2.73 vs. TGTX: $39.19)
Brand notoriety: EDIT and TGTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 75% vs. TGTX: 78%
Market capitalization -- EDIT: $228.54M vs. TGTX: $6.22B
EDIT [@Biotechnology] is valued at $228.54M. TGTX’s [@Biotechnology] market capitalization is $6.22B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileTGTX’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • TGTX’s FA Score: 1 green, 4 red.
According to our system of comparison, TGTX is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 3 TA indicator(s) are bullish while TGTX’s TA Score has 6 bullish TA indicator(s).

  • EDIT’s TA Score: 3 bullish, 5 bearish.
  • TGTX’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, TGTX is a better buy in the short-term than EDIT.

Price Growth

EDIT (@Biotechnology) experienced а -10.78% price change this week, while TGTX (@Biotechnology) price change was +4.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.49%. For the same industry, the average monthly price growth was +13.01%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

EDIT is expected to report earnings on Nov 10, 2025.

TGTX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TGTX($6.22B) has a higher market cap than EDIT($229M). EDIT YTD gains are higher at: 114.961 vs. TGTX (30.199). TGTX has higher annual earnings (EBITDA): 70.5M vs. EDIT (-244.52M). EDIT has more cash in the bank: 221M vs. TGTX (132M). TGTX has less debt than EDIT: TGTX (8.98M) vs EDIT (31.1M). TGTX has higher revenues than EDIT: TGTX (386M) vs EDIT (35.8M).
EDITTGTXEDIT / TGTX
Capitalization229M6.22B4%
EBITDA-244.52M70.5M-347%
Gain YTD114.96130.199381%
P/E RatioN/A156.76-
Revenue35.8M386M9%
Total Cash221M132M167%
Total Debt31.1M8.98M346%
FUNDAMENTALS RATINGS
EDIT vs TGTX: Fundamental Ratings
EDIT
TGTX
OUTLOOK RATING
1..100
7765
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
89
Overvalued
PROFIT vs RISK RATING
1..100
10068
SMR RATING
1..100
9946
PRICE GROWTH RATING
1..100
3642
P/E GROWTH RATING
1..100
1008
SEASONALITY SCORE
1..100
12n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (41) in the Biotechnology industry is somewhat better than the same rating for TGTX (89). This means that EDIT’s stock grew somewhat faster than TGTX’s over the last 12 months.

TGTX's Profit vs Risk Rating (68) in the Biotechnology industry is in the same range as EDIT (100). This means that TGTX’s stock grew similarly to EDIT’s over the last 12 months.

TGTX's SMR Rating (46) in the Biotechnology industry is somewhat better than the same rating for EDIT (99). This means that TGTX’s stock grew somewhat faster than EDIT’s over the last 12 months.

EDIT's Price Growth Rating (36) in the Biotechnology industry is in the same range as TGTX (42). This means that EDIT’s stock grew similarly to TGTX’s over the last 12 months.

TGTX's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for EDIT (100). This means that TGTX’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITTGTX
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TGTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RNEBX87.530.22
+0.25%
American Funds New World R2E
PIEQX18.61N/A
N/A
T. Rowe Price International Eq Index
SEEIX13.44N/A
N/A
SEI International Equity I (SIT)
LMISX25.24N/A
N/A
Franklin U.S. Large Cap Equity IS
DNSVX14.59N/A
N/A
Dunham Small Cap Value N